Solid Biosciences Inc. SLDB Derivative Liabilities - Fair Value
Derivative Liabilities - Fair Value at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.
The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s derivative liabilities - fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s derivative liabilities - fair value?
- Solid Biosciences Inc. (SLDB) reported derivative liabilities - fair value of $3.35M in Q1 2026.
- How has Solid Biosciences Inc.'s derivative liabilities - fair value changed year-over-year?
- Solid Biosciences Inc.'s derivative liabilities - fair value decreased by 30.2% year-over-year, from $4.8M to $3.35M.
- What does derivative liabilities - fair value mean?
- This metric represents the total fair market value of all derivative contracts currently in a liability position for the institution. It reflects the potential cash outflow required if these contracts were settled at the current reporting date. Monitoring this value is essential for assessing the bank's exposure to market volatility and counterparty risk.